Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Phase I protocol presented for a recessive dystrophic epidermolysis bullosa gene therapy

June 22, 2015

Immune Pharmaceuticals licenses topical ciclosporin formulation from Yissum

June 15, 2015

Tioga Pharmaceuticals begins phase II study of asimadoline in patients with pruritus

June 15, 2015

UNCOVER-1 results reveal efficacy of ixekizumab in plaque psoriasis

June 12, 2015

Ziarco's ZPL-389 enters phase IIa trial in patients with atopic dermatitis

June 11, 2015

BASF discloses oligopeptide apoptosis inhibitors

June 3, 2015

Chugai files NDA in Japan for psoriasis therapy M-8010

May 26, 2015

LEO Pharma and arGEN-X form partnership to develop antibodies for inflammatory skin disorders

May 26, 2015

R-Tech Ueno completes single-dose phase I trial of RTU-1096

May 25, 2015

Stelara recommended for European approval for plaque psoriasis in adolescents

May 25, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...